[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 5 of about 5
1. Eleutério J Jr, Giraldo PC, Cavalcante DI, Gonçalves AK, Eleutério RM, Giraldo HP: Papillary squamous cell carcinoma of the uterine cervix, high-risk human papilloma virus infection and p16(INK4a) expression: a case report. Acta Cytol; 2009 Mar-Apr;53(2):188-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papillary squamous cell carcinoma of the uterine cervix, high-risk human papilloma virus infection and p16(INK4a) expression: a case report.
  • BACKGROUND: Papillary squamous cell carcioma is rare form of squamous cell carcinoma of the uterine cervix occurring in women in the sixth decade of life and is frequently misdiagnosed as high-grade intraepithelial lesion.
  • CASE: A 58-year-old woman who had 8 gestations (no abortions) and mitral cardiopathy treated with coumarin medication was referred for transvaginal bleeding of 20 days' duration.
  • Specular examination showed an exophytic, easily bleeding lesion occupying all of the uterine cervix and superior third of the vagina.
  • Liquid-based cytology showed squamous cells, mostly basaloid but some bizarre or in fiber, with clearly atypical nuclei.
  • [MeSH-major] Carcinoma, Papillary / pathology. Carcinoma, Squamous Cell / pathology. Cyclin-Dependent Kinase Inhibitor p16 / biosynthesis. Papillomavirus Infections / complications. Uterine Cervical Neoplasms / pathology
  • [MeSH-minor] Anticoagulants / therapeutic use. Coumarins / therapeutic use. Female. Humans. Middle Aged. Mitral Valve Insufficiency / complications. Mitral Valve Insufficiency / drug therapy. Vaginal Smears


2. de la Motte Rouge T, Pautier P, Hamy AS, Duvillard P, Bruna A, Castaigne D, Morice P, Haie-Meder C, Lhommé C: [Medical treatment of metastatic or recurrent cancer of the cervix]. Bull Cancer; 2006 Mar 1;93(3):263-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Medical treatment of metastatic or recurrent cancer of the cervix].
  • Cervical cancer is the most frequent gynaecological cancer worldwide.
  • In this setting, cisplatin is considered as the drug of reference, but responses rates are poor.
  • Targeted therapeutics and immunotherapy against human papilloma virus could bear significant progress for treatment of cervical cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Uterine Cervical Neoplasms / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Clinical Trials, Phase II as Topic. Female. Humans. Immunotherapy. Middle Aged


3. O'Meara AT: Present standards for cervical cancer screening. Curr Opin Oncol; 2002 Sep;14(5):505-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Present standards for cervical cancer screening.
  • Survival rates for cancer of the uterine cervix have improved over the last 40 years largely because of the impact of screening measures such as the Pap smear.
  • The ability to screen and treat women for preinvasive disease, cervical dysplasia, is the key factor leading to the reduction in the incidence of invasive cervical cancer.
  • More recently, the ability to test women for the causative agent, the human papilloma virus, has emerged as a potential screening tool.
  • New research has focused on new technologies for Pap smear screening such as thin layer technology, the appropriate intervals for screening, and the appropriate methods of incorporation of human papilloma virus testing into the screening protocols.
  • Reviews of published studies evaluating the efficacy of new technologies suggest that there is still insufficient information to confirm improved outcome; however, results to date suggest that thin layer Pap smear technology may improve sensitivity in the detection of cervical dysplasia.
  • Some of the most important new information this year regarding cervical cancer screening includes the new Bethesda System for the reporting of Pap smears and the new guidelines for the management of the abnormal Pap smear by the American Society of Colposcopy and Cervical Pathology.
  • These guidelines incorporate human papilloma virus testing based on a multicenter trial documenting its efficacy in the triage of women with atypical squamous cells on Pap smear.
  • These recommendations are reviewed along with the current literature on cervical cancer screening.
  • [MeSH-major] Carcinoma, Squamous Cell / diagnosis. Mass Screening / standards. Practice Guidelines as Topic. Uterine Cervical Neoplasms / diagnosis


Advertisement
4. Trimble C, Lin CT, Hung CF, Pai S, Juang J, He L, Gillison M, Pardoll D, Wu L, Wu TC: Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine; 2003 Sep 8;21(25-26):4036-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe.
  • DNA vaccines have emerged as an attractive approach for antigen-specific cancer immunotherapy.
  • We have previously linked Mycobacterium tuberculosis heat shock protein 70 (HSP70) to human papillomavirus type 16 (HPV-16) E7 in the context of a DNA vaccine.
  • The success of our strategy has led to two phases I/II clinical trial proposals in patients with HPV-16 associated high-grade squamous intraepithelial lesion (HSIL) of the cervix and in patients with advanced HPV-associated head and neck squamous cell carcinoma (HNSCC).
  • To translate our HPV DNA vaccines into the clinical domain, the efficacy of pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine and of various routes of administrations were assessed in mice.
  • Our results indicated that pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine administered via gene gun generated the highest number of E7-specific CD8+ T cells.
  • [MeSH-major] CD8-Positive T-Lymphocytes / immunology. Cancer Vaccines / administration & dosage. Cancer Vaccines / immunology
  • [MeSH-minor] Animals. Antibody Specificity. Biolistics. Cytokines / biosynthesis. Female. Flow Cytometry. HSP70 Heat-Shock Proteins / immunology. Injections, Intramuscular. Interferon-gamma / biosynthesis. Mice. Mice, Inbred C57BL. Papilloma / drug therapy. Papilloma / pathology. Papilloma / prevention & control. Papillomaviridae / immunology. Plasmids / genetics. Vaccines, DNA / administration & dosage. Vaccines, DNA / immunology

  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12922140.001).
  • [ISSN] 0264-410X
  • [Journal-full-title] Vaccine
  • [ISO-abbreviation] Vaccine
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Cytokines; 0 / HSP70 Heat-Shock Proteins; 0 / Vaccines, DNA; 82115-62-6 / Interferon-gamma
  •  go-up   go-down


5. Park TC, Kim CJ, Koh YM, Lee KH, Yoon JH, Kim JH, Namkoong SE, Park JS: Human papillomavirus genotyping by the DNA chip in the cervical neoplasia. DNA Cell Biol; 2004 Feb;23(2):119-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human papillomavirus genotyping by the DNA chip in the cervical neoplasia.
  • Human papillomavirus (HPV) is implicated as an etiologic agent in neoplasitc lesions of the cervix.
  • In this study, we used an HPV DNA chip to detect the type-specific sequence of HPV from cervical swabs in women with biopsy- proven neoplastic lesions of the cervix.
  • Four hundred seventy-one patients were involved and classified into four groups based on the cytopathologic diagnosis: group I (normal, n = 290), group II (low-grade squamous intraepithelial lesions (SIL), n = 68), group III (high-grade SIL, n = 51), and group IV (invasive cervical cancer, n = 55).
  • HPV detection rates were 17.6% (51 of 290), 73.5% (50 of 68), 92.2% (47 of 51), and 95.2% (59 of 62) in patients of group I to group IV, respectively.
  • HPV-16 was the most frequent type (21.8%) in all specimens tested, and significantly increased the prevalence by advancing the grade of the cervical lesions (P < 0.01).
  • This suggests that the HPV DNA chip is a sensitive diagnostic tool for the detection of HPV in cervical specimens, and that it would provide more useful information on viral genotype and multiple HPV infections.
  • Taken together, molecular biological data on HPV might be beneficial for the prevention and management of cervical neoplastic lesions.
  • [MeSH-major] Papilloma / genetics. Papillomaviridae / genetics. Papillomavirus Infections / genetics. Uterine Cervical Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15000752.001).
  • [ISSN] 1044-5498
  • [Journal-full-title] DNA and cell biology
  • [ISO-abbreviation] DNA Cell Biol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down






Advertisement